Drag a card by its title · ⚙ to size, swap or remove

The company

Fortress Biotech, Inc.

FBIO · Nasdaq

Health CareBiotechnologyNot moving yet

FBIO stood above a rising 150-day average in 27 of the last 52 weekly readings, and has been out of that trend for the last 11 weeks. It is 30.5% below that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).

SEC filings

Statistics

Rotation: Not moving yet
Weeks in an uptrend: out for 11
Industry in uptrend: 15% -17 in 4 wk
Insider buys, 12 months: $0
Insider sales, 12 months: $0
Officials’ trades on record: 0
Institutions holding: 52 (+4)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 27 of 52 weeks.

17 Apr – 16 Oct

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0

Sale orders, 12 months0

Buyers · sellers0 · 0

No open-market buy or sale by its insiders on record.

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders52+4 on the quarter

New · exited14 · 10

Reported value$15.1M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

Manager	Shares	Change
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 2026	1,037,203$3.2M	+71,173+7.4%
Opaleye Management Inc.reduced · filed 14 Aug 2026	890,000$2.7M	-152,000−14.6%
MACKENZIE FINANCIAL CORPnew · filed 13 Aug 2026	555,676$1.7M	+555,676
GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 2026	300,521$920K	+10,266+3.5%
BlackRock, Inc.added · filed 7 Aug 2026	224,782$688K	+27,697+14.1%
TWO SIGMA INVESTMENTS, LPadded · filed 14 Aug 2026	213,786$654K	+16,961+8.6%
BRIDGEWAY CAPITAL MANAGEMENT, LLCreduced · filed 14 Aug 2026	177,368$543K	-5,000−2.7%
VANGUARD FIDUCIARY TRUST COadded · filed 13 Aug 2026	166,371$509K	+23,836+16.7%
HB Wealth Management, LLCreduced · filed 29 Jul 2026	116,675$357K	-3,500−2.9%
Kestra Advisory Services, LLCreduced · filed 28 Jul 2026	116,235$356K	-13,566−10.5%

30 Sep 2023 – 30 Jun 2026

News

No headline names it lately.

Everyone who traded it

David Jin Chief Financial Officer · last 1 Oct 20263 · 0

Lindsay A. Rosenwald PRESIDENT, CEO & CHAIRMAN · last 18 Mar 202637 · 0

Michael S. Weiss Executive Vice Chairman · last 18 Mar 20263 · 0

Dov Klein Director · last 1 Jan 20260 · 2

J. Jay Lobell Director · last 1 Jan 20264 · 0

Jimmie Harvey Director · last 1 Jan 20260 · 0

Kevin Lorenz Director · last 1 Jan 20262 · 0

Malcolm Hoenlein Director · last 1 Jan 20262 · 0

Lucy Lu Director · last 1 Jan 20259 · 0

Eric K. Rowinsky Director · last 1 Jan 20241 · 5

Robyn Hunter Chief Financial Officer · last 21 Sep 20211 · 3

George Avgerinos SVP, BIOLOGICS OPERATIONS · last 17 Apr 20190 · 6

Same industry

MRNA ModernaLeading+147%

IOVA Iovance BiotherapeuticsLeading+126%

ABCL AbCellera BiologicsLeading+60%

HALO Halozyme TherapeuticsLeading+46%

XERS Xeris Biopharma HoldingsLeading+38%

ENTX Entera BioLeading+37%

HELP Helus PharmaLeading+36%

XNCR XencorLeading+30%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Profit per saleFY 2025 · to 31 Dec 202566.9%

Operating profit marginFY 2025 · to 31 Dec 2025-111%

Free cash flow marginFY 2024 · to 31 Dec 2024-139%

Return on capital employedFY 2025 · to 31 Dec 2025-51.7%

Cash conversionFY 2025 · to 31 Dec 2025-965%

Debt to equityFY 2025 · to 31 Dec 20251.05×

Interest coverFY 2025 · to 31 Dec 2025-6.95×

Cash and equivalentsFY 2025 · to 31 Dec 2025$79.4M

Free cash flowFY 2024 · to 31 Dec 2024−$80.2M

Analyst forecasts

No analyst forecasts yet.